Big Pharma companies changed up their R&D programs in 2011 – Pfizer pursued a major reduction, AstraZeneca, GlaxoSmithKline and other rebooting their programs. This year, some companies have been trying to outsource their development.
There has also been a shift from west to east in R&D. Attracted by much lower costs, Big Pharma companies are looking at China and other emerging markets.
The most exciting change for scientists is the growing demand for open innovation networks. J&J, for example, has led the charge for investigators involved in neuroscience to pool their efforts in “precompetitive” arenas.
To read the full article, click here.
To learn more about R&D and open innovation networks, click here.